Scientist stories

Simon specialises in cancers of the genitourinary tract including bladder, prostate and adrenal cancers. He plays a lead role in the delivery of early phase cancer clinical trials at Southampton.

Peter gained accreditation in medical oncology in 1994. He has extensive experience in managing malignant lymphomas, including high dose therapy and stem cell transplantation.

In 2014, Gareth returned to Southampton as a professor of clinical trials. He took on directorship of the clinical trials unit. He found passion for cancer research everywhere, and wanted to help it develop and expand.

Mark uncovers how the immune system interacts with cancer cells and how it can be harnessed in the form of immunotherapy to treat malignancy, particularly by using drugs called monoclonal antibodies.

Tim joined the CCI in 2022. He studies a group of seven genes called APOBECs and their role in how successful cancer treatments are.

Juliet leads new UK immunotherapy studies which look at improving neuroblastoma treatments and their effectiveness.

Ali's celebrated career in cancer immunology has touched both academia and industry. He has led an independent research group at the University since the CCI opened in 2018.

Sally and Raimund’s work uses antibody engineering, fluorescence microscopy and mouse models. Their potential antibody-based therapeutics have moved into clinical trials through licensing to pharmaceutical companies.

Sean is funded by a Cancer Research UK Advanced Clinician Scientist Fellowship, helping her to bridge the divide between laboratory and clinic.

Max is an associate member of the CCI. His research into breast cancer is funded by Against Breast Cancer.

Following her degree in biology, Sarah continued her studies at Southampton with a PhD. She studies CD8 positive T cells – the foot soldiers of the immune system.